Skip to main content

Table 3 Clinical Response

From: Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Characteristic

All evaluable patients (n = 24)

Best radiographic response

 

 Complete response (CR), no. (%)

0 (0)

 Partial response (PR), no. (%)

2 (8)

 Stable disease (SD), no. (%)

5 (21)

 Progressive disease (PD), no. (%)

17 (71)

Median PFS, days (range)

42 (7–282)

Median OS, days (range)

121 (15–415)